Evolent Health (NYSE:EVH) Posts Earnings Results, Hits Expectations

Evolent Health (NYSE:EVH) released its quarterly earnings data on Thursday. The technology company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.06, FiscalAI reports. Evolent Health had a negative return on equity of 5.98% and a negative net margin of 21.67%. The company had revenue of $725.37 million during the quarter, compared to analysts’ expectations of $727.06 million. During the same period last year, the firm posted $0.05 earnings per share. The business’s revenue was up 51.3% on a year-over-year basis.

Here are the key takeaways from Evolent Health’s conference call:

• Q3 growth and higher earnings outlook: Revenue rose 11% sequentially to $725 million and adjusted EBITDA increased 22% to $34.3 million. Evolent raised its 2026 adjusted EBITDA guidance to $130 million–$135 million while reaffirming revenue guidance of $2.6 billion–$2.7 billion.
• Customer renewals and expansions: Evolent renewed its largest Surgical Management contract for four years and announced oncology and specialty-services expansions, including an additional 11 states for a national payer. The company said these agreements reflect opportunities to deepen relationships and broaden its product offerings.
• Medical expense performance improved: The medical expense ratio fell to 93% from 95% in Q2, helped by favorable claims development and contractual adjustments. Management expects a smaller sequential improvement in Q4 because some favorable claims development came through earlier than expected, while reiterating full-year MER guidance of approximately 93%.
• AI may support efficiency and growth, but returns are still ahead: AuthIntelligence now evaluates about half of prior authorizations that previously needed manual review, and Evolent expects to expand its use through 2027. Management sees potential for lower costs and market-share gains, but expects higher AI-related capital expenditures in 2027, with returns beginning late in that year.
• Cash generation and leverage remain challenges: Evolent ended Q3 with $148 million of unrestricted cash and $776 million of net debt, and expects full-year operating cash flow of just $10 million–$20 million after cash interest. It is targeting up to $50 million of debt reduction by year-end, while citing membership attrition and contract scope adjustments as 2027 headwinds.

Evolent Health Stock Performance

EVH stock traded up $0.07 during mid-day trading on Friday, hitting $4.61. 1,743,939 shares of the company were exchanged, compared to its average volume of 1,821,422. Evolent Health has a 1-year low of $2.10 and a 1-year high of $6.28. The stock has a market capitalization of $520.64 million, a PE ratio of -1.01 and a beta of 1.03. The business has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $3.88. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Oppenheimer raised its price target to $7 from $6 and maintained an “outperform” rating, implying substantial upside from the cited $4.61 share price. Oppenheimer recommendations
• Positive Sentiment: Needham & Company lifted its target to $6 from $5 and kept a “buy” rating, adding to the favorable analyst outlook. Needham recommendations
• Positive Sentiment: EVH forecast fiscal 2026 revenue of $2.6 billion to $2.7 billion, with the top of the range above analysts’ $2.6 billion consensus. Third-quarter results and outlook
• Neutral Sentiment: Third-quarter adjusted earnings were $0.06 per share, matching estimates and improving from $0.05 a year earlier. Revenue rose 51.3% year over year to $725.37 million, but was slightly below the $727.06 million consensus. Third-quarter results
• Negative Sentiment: The reported quarter included a negative net margin of 24.08% and negative return on equity, highlighting that profitability remains a concern despite revenue growth and per-share earnings. Third-quarter results

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EVH shares. Oppenheimer boosted their target price on Evolent Health from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday. TD Cowen raised their price target on Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a report on Monday, August 17th. Truist Financial cut their price target on Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. JPMorgan Chase & Co. lifted their price objective on shares of Evolent Health from $5.00 to $6.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 18th. Finally, Needham & Company LLC upped their price objective on shares of Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.11.

Insider Activity at Evolent Health

In other news, President Daniel Mccarthy sold 65,892 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total value of $329,460.00. Following the transaction, the president owned 655,133 shares of the company’s stock, valued at approximately $3,275,665. This represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.48% of the company’s stock.

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.